To be or not to be (inflamed) - Is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?

Trends in Pharmacological Sciences

Volumn 26, Issue 10, 2005, Pages 517-525

  Marchetti, Bianca ^a,b   Abbracchio, Maria P ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CANNABINOID DERIVATIVE; CANNABIS; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; FLAVONOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSANOID; METAL CHELATE; MORPHINAN DERIVATIVE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROFECOXIB; TETRACYCLINE DERIVATIVE; VALDECOXIB;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLON ADENOMA; DEGENERATIVE DISEASE; DEMYELINATION; DISEASE MARKER; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ENCEPHALITIS; GENE EXPRESSION REGULATION; GENOTYPE ENVIRONMENT INTERACTION; GLIOSIS; HEART INFARCTION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RHEUMATOID ARTHRITIS; STROKE; THROMBOEMBOLISM; TREATMENT FAILURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ENCEPHALITIS; HUMANS; IMMUNITY, NATURAL; NEURODEGENERATIVE DISEASES;

EID: 25144468525     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.08.007     Document Type: Review

References (75)

1. C. Gorman, and A. Park The fires within Time 1 2004 45 51
2. M. Schiess Non steroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arch. Neurol. 60 2003 1043 1044
3. M. Hauwel Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, "protective" glial stem cells and stromal ependymal cells Brain Res. Brain Res. Rev. 48 2005 220 233
4. J.R. Faulkner Reactive astrocytes protect tissue and preserve function after spinal cord injury J. Neurosci. 24 2004 2143 2155
5. P. Patrignani New insight into COX-2 biology and inhibition Brain Res. Brain Res. Rev. 48 2005 352 359
6. R. Brambilla, and M.P. Abbracchio Modulation of cyclooxygenase-2 and brain reactive astrogliosis by purinergic P2 receptors Ann. New York Acad. Sci. 939 2001 54 62
7. B. Marchetti Glia-neuron crosstalk in neuroinflammation, neurodegeneration and neuroprotection Brain Res. Brain Res. Rev. 48 2005 129 408
8. C.M. Liberto Pro-regenerative properties of cytokine-activated astrocytes J. Neurochem. 89 2004 1092 1100
9. M.L. Monje Inflammatory blockade restores adult hippocampal neurogenesis Science 302 2003 1760 1765
10. W.J.S. Streit Microglia and neuroprotection: implication for Alzheimer's disease Brain Res. Brain Res. Rev. 48 2005 234 239
11. F.L. Heppner Experimental autoimmune encephalomyelitis repressed by microglial paralysis Nat. Med. 11 2005 146 152
12. M. Schwartz, and J. Kipnis Protective autoimmunity in inflammatory and non inflammatory neurodegenerative diseases J. Neurol. Sci. 233 2005 163 166
13. T.T. Warner, and A.H.V. Schapira Genetic and environmental factors in the cause of Parkinson's disease Ann. Neurol. 53 2003 S16 S25
14. I. Rainero Association between the interleukin-1alpha gene and Alzheimer's disease: a meta-analysis Neurobiol. Aging 25 2004 1293 1298
15. C. Levecque Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study Hum. Mol. Genet. 12 2003 79 86
16. Marchetti, B. et al. (2001) The hypothalamic-pituitary-gonadal axis and the immune system. In PsychoNeuro-Immunology (Vol. 1, 3rd Edn), pp. 363-387, Raven Press
17. D. Franchimont Overview if the actions of glucocorticoids on the immune response: good model to characterize new pathways of immunosuppression for new treatments Ann. New York Acad. Sci. 1024 2004 124 137
18. D. Garcia-Ovejero Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones Brain Res. Brain Res. Rev. 48 2005 273 286
19. M.C. Morale Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide FASEB J. 18 2003 164 166
20. B. Marchetti Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions Brain Res. Brain Res. Rev. 48 2005 302 321
21. Morale, M.C. et al. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience (in press)
22. A. Hakansson Interaction of polymorphisms in the genes encoding intereukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease Am. J. Med. Genet. B Neuropsychiatr. For. Genet. 133 2005 88 92
23. E. Vegeto Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol Proc. Natl. Acad. Sci. U. S. A. 100 2003 9614 9619
24. B. Marchetti Stress, the immune system and vulnerability to degenerative disorders of the central nervous system in transgenic mice expressing glucocorticoid receptor antisense RNA Brain Res. Brain Res. Rev. 37 2001 259 272
25. H.M. Gao Novel anti-inflammatory therapy for Parkinson's disease Trends Pharmacol. Sci. 24 2003 395 401
26. Z.D. Ling Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain Neuroscience 124 2004 619 628
27. P. Dahlqvist Environmental enrichment reverses learning impairment in the Morris water maze after focal cerebral ischemia in rats Eur. J. Neurosci. 19 2004 2288 2298
28. T.L. Spires Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism J. Neurosci. 24 2004 2270 2276
29. S.L. Arnaiz Enriched environment, nitric oxide production and synaptic plasticity prevent the aging-dependent impairment of spatial cognition Mol. Aspects Med. 25 2004 91 101
30. L.C. Alvaro-Gonzalez Inflammatory mechanisms, arteriosclerosis and ischemic stroke: clinical data and perspectives Rev. Neurol. 35 2002 452 462
31. H.C. Emsley, and P.J. Tyrrell Inflammation and infection in clinical stroke J. Cereb. Blood Flow Metab. 22 2002 1399 1419
32. D. Frenkel Nasal vaccination with myelin oligodendrocyte glycoprotein reduces stroke size by inducing IL-10-producing CD4+ T cells J. Immunol. 171 2003 6549 6555
33. T. Miida Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia J. Atheroscler. Thromb. 11 2004 253 264
34. C.W. Olanov Neuroprotection for Parkinson's disease: prospects and promises Ann. Neurol. 53 Suppl. 3 2003 S1 S2
35. P.L. McGeer, and E.G. McGeer Inflammation and neurodegeneration in Parkinson's disease Parkinsonism Relat. Disord. 10 Suppl. 1 2004 S3 S7
36. A. Hartmann Inflammation and dopaminergic neuronal loss in Parkinson' disease: a complex matter Exp. Neurol. 184 2003 561 564
37. P. Teismann COX-2 and neurodegeneration in Parkinson's disease Ann. New York Acad. Sci. 991 2003 272 277
38. D.C. Wu Blockade of microglia activation is neuroprotective in the MPTP mouse model of Parkinson's disease J. Neurosci. 22 2002 1763 1771
39. H. Chen Nonsteroidal anti-inflammatory drugs and the risk of Parkinson's disease Arch. Neurol. 60 2003 1059 1064
40. E.J. Benner Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease Proc. Natl. Acad. Sci. U. S. A. 101 2004 9435 9440
41. T. Dehmer Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation J. Neurochem. 88 2004 494 501
42. A. Prat, and J. Antel Patohogenesis of multiple sclerosis Curr. Opin. Neurol. 18 2005 225 230
43. T. Owens Cytokine and chemokine inter-regulation in the inflammed or injured CNS Brain Res. Brain Res. Rev. 48 2005 178 184
44. J.J. Hendriks Macrophages and neurodegeneration Brain Res. Brain Res. Rev. 48 2005 185 195
45. D.O. Willenborg Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review J. Neuroimmunol. 100 1999 21 35
46. P. Drew Hormone regulation of microglial cell activation: relevance to multiple sclerosis Brain Res. Brain Res. Rev. 48 2005 322 327
47. B. Marchetti Exposure to a dysfunctional glucocorticoid receptor from early embryonic life programs the resistance to experimental allergic encephalomyelitis via nitric oxide-induced immunosuppression J. Immunol. 168 2002 5848 5859
48. A.E. Lovett-Racke Peroxisome prolferator activated receptor alpha agonists as therapy for autoimmune diseases J. Immunol. 172 2004 5790 5798
49. C. Moon Sodium salicylate-induced amelioration of experimental allergic encephalomyelitis in Lewis rats is associated with suppression of inducible nitric oxide synthase and cyclooxygenases Neurosci. Lett. 356 2004 123 126
50. R. Furlan A nitric oxide derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis J. Neuroimmunol. 150 2004 10 19
51. L. Walter, and N. Stella Cannabinoids and neuroinflammation Br. J. Pharmacol. 141 2004 775 785
52. O. Neuhaus Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection Trends Pharmacol. Sci. 24 2003 131 138
53. G. Martino How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders Lancet Neurol. 3 2004 372 378
54. S. Pluchino Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism Nature 436 2005 266 271
55. P.L. McGeer Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies Neurology 47 1996 425 432
56. P.P. Zandi Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study Neurology 59 2002 880 886
57. P. Eikelenboom, and W.A. van Gool Neuroinflammatory perspectives on the two faces of Alzheimer's disease J. Neural Transm. 111 2004 281 294
58. G.M. Pasinetti, and P.N. Pompl Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed? Lancet Neurol. 1 2002 403 404
59. M. Cacquevel Cytokines in neuroinflammation and Alzheimer's disease Curr. Drug Targets 5 2004 529 534
60. G.M. Cole NSAID and antioxidant prevention of Alzheimer's Disease: lessons from in vitro and animal models Ann. New York Acad. Sci. 1035 2004 68 84
61. W.A. van Gool Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J. Neurol. 250 2003 788 792
62. P.S. Aisen Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial J. Am. Med. Assoc. 289 2003 2819 2826
63. M. Koistinaho, and J. Koistinaho Interactions between Alzheimer's disease and cerebral ischemia - focus on inflammation Brain Res. Brain Res. Rev. 48 2005 240 250
64. S. Mandel Mechanism of neuroprotective action of the antiParkinson drug rasagiline and its derivatives Brain Res. Brain Res. Rev. 48 2005 379 387
65. V.H. Perry The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease Brain Behav. Immun. 18 2004 407 413
66. K.S. Krabbe Inflammatory mediators in the elderly Exp. Gerontol. 39 2004 687 699
67. S. Mandel, and M.B.H. Youdim Catechin polyphenols, neurodegeneration and neuroprotection in neurodegenerative diseases Free Radic. Biol. Med. 37 2004 304 317
68. M. Ankarcrona, and B. Winblad Biomarkers for apoptosis in Alzheimer's disease Int. J. Geriatr. Psychiatry 20 2005 101 105
69. R.B. Banati Visualising microglia activation in vivo Glia 40 2002 206 217
70. M. Kassiou Ligands for peripheral benzodiazepine binding sites in glial cells Brain Res. Brain Res. Rev. 48 2005 207 210
71. L. Ho From proteonomic to biomarker discovery in Alzheimer's disease Brain Res. Brain Res. Rev. 48 2005 360 369
72. W.E. Ollier Cytokine genes and disease susceptibility Cytokine 28 2004 174 178
73. S.A. Wirz High frequency of TNF alleles and -376A in individuals from northern Sardinia Cytokine 26 2004 149 154
74. F. Licastro A polymorphism of the interleukn-1 beta gene at position +3953 influences the progression and neuro-pathological hallmarks of Alzheimer's disease Neurobiol. Aging 25 2004 1017 1022
75. L. Capecchi Upregulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation J. Card. Fail. 11 2005 67 73